Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 11, Number 8—August 2005

Research

Cephalosporin-resistant Pneumococci and Sickle Cell Disease

Martha L. Miller*1, Caroline A. Obert*1, Geli Gao*, Najat C. Daw*, Patricia Flynn*, and Elaine Tuomanen*Comments to Author 
Author affiliations: *St. Jude Children's Research Hospital, Memphis, Tennessee, USA

Main Article

Table 2

Multilocus sequence types of penicillin- and cephalosporin-resistant isolates*

Strain Serotype Allele numbers
 Sequence type Resistance
 MIC values
aroE gdh gki recP spi xpt ddl PNV CTX PNV CTX
38 3 8 37 9 29 2 12 NA Novel I S 0.38 0.50
3 3 7 15 2 10 6 1 22 180 S
52 4 10 5 4 5 13 10 18 205 S
46 4 10 5 4 5 13 10 18 205 S
61 4 16 13 4 4 6 10 18 899 S
48 6 8 37 9 29 2 12 53 344 I S 0.38 0.19
1 6 7 6 9 2 6 1 67 384 I I 1.00 0.75
49 6 5 7 4 10 10 1 27 460 I NA 0.38
63 6 5 7 4 10 10 1 27 460 I S 0.38 0.50
35 6 1 25 1 8 15 20 14 660 I I 1.00 0.75
81 6 1 25 72 1 15 20 28 690 I S 0.094 0.094
84 6 2 13 8 6 6 3 NA 1754 I NA 0.25
75 6 7 25 4 4 15 20 NA Novel I S 0.094 0.094
13 6 1 5 4 5 5 3 101 NT3 I S 0.38 0.19
29 6 1 5 4 5 5 3 101 NT3 I S 0.94 0.25
19 6 7 6 9 2 6 1 67 384 R R 3.00 3.00
33 6 7 6 1 2 6 15 14 146 S
37 6 7 6 1 2 6 15 14 146 S
40 6 7 6 1 2 6 15 14 146 S
45 6 7 6 1 2 6 15 14 146 S
39 6 7 13 8 6 10 6 14 176 S
76 6 7 15 2 10 6 1 22 180 S
44 6 1 5 1 5 1 1 8 425 S
85 6 7 25 4 4 15 20 1 647 S
30 6 1 25 72 1 15 20 28 690 S
43 6 1 25 72 1 15 20 28 690 S
31 6 7 61 1 1 17 1 NA 1752 S
4 11 2 5 29 12 16 3 14 62 S
20 11 2 5 29 12 16 3 14 62 S
22 14 2 8 7 4 6 1 1 67 R I 4.00 1.00
27 14 2 8 7 4 6 1 1 67 R I 4.00 1.00
57 14 2 8 7 4 6 1 1 67 R I 2.00 1.00
59 14 2 8 7 4 6 1 1 67 R I 3.00 1.50
74 14 1 5 4 5 5 27 8 13 S
56 14 7 5 1 8 14 11 14 124 S
83 14 7 5 1 8 14 11 14 124 S
28 15 8 6 14 4 17 4 14 1755 S
69 15 8 13 1 4 17 4 14 1757 S
71 15 8 13 1 4 17 4 14 1757 S
60 19 8 13 14 4 17 4 14 199 I S 0.125 0.064
70 19 8 13 14 4 17 4 14 199 I S 0.190 0.094
79 19 8 13 14 4 17 4 14 199 I S 0.125 0.064
80 19 8 13 14 4 17 4 14 199 I S 0.094 0.064
24 19 15 16 19 15 6 20 26 236 I S 0.25 0.25
34 19 15 16 19 15 6 20 26 236 I S 0.25 0.25
65 19 15 16 19 15 6 20 26 236 I I 1.00 0.75
42 19 8 20 14 4 17 4 14 1756 I S 0.190 0.094
77 19 8 20 14 4 17 4 14 1756 I S 0.125 0.094
78 19 8 20 14 4 17 4 14 1756 I S 0.190 0.064
41 19 15 NA NA NA 6 NA NA Novel I S 0.25 0.19
32 19 1 10 4 1 9 3 8 43 S
15 19 8 13 14 4 6 4 14 876 S
68 22 1 1 4 1 18 58 17 433 S
2 23 1 8 6 2 6 4 6 37 I R 1.00 1.50
53 23 1 8 6 2 6 4 6 37 I R 0.125 1.50
26 23 1 8 6 2 6 4 6 37 R R 4.00 6.00
47 23 1 8 6 2 6 4 6 37 R R 8.00 8.00
62 23 1 8 6 2 6 4 6 37 R R 3.00 8.00
58 23 1 8 6 2 6 4 NA 1753 R R 3.00 8.00
86 23 1 8 9 2 6 4 6 439 S
14 23 13 8 9 2 6 4 6 1499 S
55 ND 29 33 19 1 36 22 31 447 S
66 ND 5 5 6 1 9 10 14 547 S
25 ND 7 9 NA 1 14 48 14 Novel S

*PNV, penicillin V; CTX, cefotaxime; S, susceptible; I, intermediate; R, resistant; NT, nontypeable; NA, not available; ND, not done.

Main Article

1These authors contributed equally to this study.

Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external